Abstract Number: 2403 • 2013 ACR/ARHP Annual Meeting
The Incidence Of Factor V Leiden A1691G, Methylene Tetrahydrofolate Reductase C677T, and Prothrombin G20210A Mutation In Patients With Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic and inflammatory disease. Thromboembolic phenomenas are more frequent in patients with RA than healthy individuals and several…Abstract Number: 2404 • 2013 ACR/ARHP Annual Meeting
CXCL13-Producing CD4 T-Cells In Rheumatoid Synovitis Are a Distinct Subset
Background/Purpose: Ectopic lymphoid structures are frequently formed in synovial tissues of patients with rheumatoid arthritis (RA). Several reports suggested that CD4 T-cells have a crucial…Abstract Number: 2405 • 2013 ACR/ARHP Annual Meeting
Respiratory Diseases As Risk Factors For Rheumatoid Arthritis
Background/Purpose: The etiology of rheumatoid arthritis (RA) is only partly understood. In addition to smoking, other airway exposures, e.g. silica dust and traffic pollution, have…Abstract Number: 2406 • 2013 ACR/ARHP Annual Meeting
The Relationship Between Anti-Citrullinated Protein Antibodies and Radiographic Damage In African-Americans With Rheumatoid Arthritis
Background/Purpose: Joint erosions and joint space narrowing may lead to impaired functional status and disability in rheumatoid arthritis (RA). Autoantibodies to citrullinated proteins (ACPA) are present in…Abstract Number: 2407 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Related Autoantibodies In The Lung Evolve Over Time In Subjects At Elevated Risk For Future Rheumatoid Arthritis
Background/Purpose: Recent data from our group have demonstrated that RA-related autoantibodies (Abs), including anti-CCP and RF, are detectable in sputum from subjects with early Classified…Abstract Number: 2408 • 2013 ACR/ARHP Annual Meeting
Secretory Leukocyte Protease Inhibitor Released By Rheumatoid Synovial Fibroblasts Exerts a Negative Control Of BAFF-Dependent B Cell Activation In Vitro and In Vivo In The Collagen-Induced and Chimeric RA/SCID Arthritis Models
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the formation of synovial niches of autoreactive B cells which are favored by the autocrine production of B…Abstract Number: 2409 • 2013 ACR/ARHP Annual Meeting
Association Of High Serum Interleukin-23 Levels With Porphyromonas Gingivalis Antibodies In Patients With Early Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased frequency of periodontal disease (PD) and antibodies to P. gingivalis (Pg), a major periodontal pathogen. Both…Abstract Number: 2410 • 2013 ACR/ARHP Annual Meeting
Effects Of Leptin and Adiponectin On Proliferation and Activation Were Are Significantly Increased In CD4+ T Cells From Rheumatoid Arthritis Patients
Background/Purpose: In vitro and in vivo studies suggest that leptin and adiponectin are involved in the development of inflammation in RA patients. Previous findings by…Abstract Number: 2371 • 2013 ACR/ARHP Annual Meeting
Is a Single Variable, The Swollen Joint Count, Valid As An Outcome Measure Separate From Being In An Index Measure? An Analysis From The Prospective, Biologic Treatment Registry Across Canada
Background/Purpose: The importance of joint counts as measures of synovitis is reflected in their prominence in all major clinical composite indices, the Disease Activity Score…Abstract Number: 2372 • 2013 ACR/ARHP Annual Meeting
Comparison Of Proposed Biosimilar PF-05280586 With Rituximab: Nonclinical and Phase I Clinical Assessments
Background/Purpose: PF-05280586 is being developed as a potential biosimilar to rituximab, a monoclonal antibody (mAb) approved for the treatment of moderate-to-severe rheumatoid arthritis and lymphomas.…Abstract Number: 2373 • 2013 ACR/ARHP Annual Meeting
UK Clinical Practice Use Of Biologics In Monotherapy For The Treatment Of Patients With Rheumatoid Arthritis
Background/Purpose: NICE guidelines recommend that patients with severe active rheumatoid arthritis (RA) be treated with a biologic disease‑modifying anti‑rheumatic drug as monotherapy (bDMARD mono) if…Abstract Number: 2374 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects
Background/Purpose: Anti-cytokine therapies have become the mainstay of treatment for rheumatoid arthritis (RA) disease symptoms and can arrest disease progression. Despite numerous treatment options there…Abstract Number: 2375 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Glucocorticoids Sparing Effect: The Spare-1 Study
Background/Purpose: Although glucocorticoids (GCs) may be appropriate in rheumatoid arthritis (RA), there is general agreement that GCs sparing is desirable. The safety of GCs is…Abstract Number: 2376 • 2013 ACR/ARHP Annual Meeting
A Novel and Effective Prediction Model Of Response To Rituximab In Rheumatoid Arthritis
Background/Purpose: For patients with rheumatoid arthritis (RA) who are refractory to tumor necrosis factor (TNF)-inhibitors, it is still not clear which determinants are associated with…Abstract Number: 2377 • 2013 ACR/ARHP Annual Meeting
Biomarkers Associated With Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate With Changes In Clinical Response In Subjects Treated With Mavrilimumab At Doses Above 10 Mg
Background/Purpose: GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through effects on macrophages and neutrophils. Mavrilimumab (CAM-3001) is a human monoclonal…
ACR Meeting Abstracts